Skip to main content

Table 2 Primary and secondary outcomes

From: An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born <28 weeks’ gestation: results of the TIPIT trial

 

LT4 -supplemented

Placebo

Difference (95% CI) LT4 - placebo

P value

Subarachnoid space width at 36 weeks’ CGA (cm)

0.20 (0.06)

0.21 (0.062

−0.01 (−0.03, 0.01)

0.34

n=61

n=57

Head circumference at 36 weeks’ CGA (cm)

30.40 (1.90)

30.61 (2.23)

−0.2 (−0.96, 0.54)

0.49

n=61

n=57

Leg length at 36 weeks’ CGA (mm)

61.52 (8.90)

65.20 (7.11)

−3.80 (−6.91, -0.62)

0.02

n=53

n=53

Mid arm circumference at 36 weeks’ CGA (mm)

8.03 (1.07)

8.19 (1.18)

−0.15 (−0.57, 0.25)

0.47

n=60

n=57

Weight at 36 weeks’ CGA (kg)

1.90 (0.40)

2.03 (0.40)

−0.11 (−0.26, 0.04)

0.14

n=61

n=57

Thyroid volume (mL) at 36 weeks’ CGA

0.57 (0.17)

0.57 (0.17)

0.004 (−0.07, 0.06)

0.99

n=59

n=55

Mortality

14 (18%)

19 (24%)

−0.06(−0.19, 0.08)

0.34

n=75

n=78

Duration of mechanical ventilation (days)

18.30 (13,38)

21.00 (8,42)

−2.00 (−5.00, 8.00)

0.56a

n=58

n=58

Days on total parenteral nutrition (TPN)

14.00 (10,21)

14.50 (11,21)

−1.00 (−4.00, 2.00)

0.59a

n=58

n=58

Chronic lung disease (CLD) diagnosed

42 (56%)

39 (50%)

0.06 (−0.10, 0.22)

0.46

n=61

n=57

Oxygen levels at 36 weeks’ CGA(L/min) for babies with CLD

0.50 (0.08, 1.5)

0.30 (0.08, 1.5)

0.00 (−0.17, 0.20)

0.99a

n=61

n=57

  1. Data expressed as mean and standard deviation (SD) for continuous parametric outcomes and median and interquartile range (IQR) for non-parametric outcomes.
  2. Student t-test for analysis of continuous parametric outcomes.
  3. aMann-Whitney Wilcoxon test for non-parametric outcomes.